Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propofol Medium and Long Chain Fat Emulsion Injection
- Development stage
- Unknown
- Lead developer
- Haisco Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol Medium and Long Chain Fat Emulsion Injection is an intravenous general anesthetic and sedative developed by Haisco Pharmaceutical Group Co., Ltd. The active ingredient, propofol, is a small molecule that acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor complex, facilitating inhibitory neurotransmission in the central nervous system. This specific formulation utilizes a lipid vehicle composed of both medium-chain triglycerides (MCT) and long-chain triglycerides (LCT). Compared to traditional long-chain triglyceride-only propofol emulsions, the MCT/LCT formulation is designed to reduce the concentration of free propofol in the aqueous phase, thereby potentially decreasing the incidence of injection-site pain and improving the lipid metabolism profile during prolonged administration. It is indicated for the induction and maintenance of general anesthesia and for sedation in intensive care or diagnostic procedures.
- Other names
- Propofol MCT/LCTPropofol Medium/Long Chain Fat Emulsion
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on Propofol Medium and Long Chain Fat Emulsion Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Propofol Medium and Long Chain Fat Emulsion Injection.